newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs Blog Sign in Sign up

newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs Blog Sign in Sign up

newsimpactscreener— news connected to markets.

@newsimpactscrnr on X @newsimpactscreener on Instagram About Briefings Terms Privacy

newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs BlogSign in Sign up

Here's Why You Should Add Inogen Stock to Your Portfolio Now — INGN +0.60 · News Impact Screener

Back to The Tape

Zacks Investment Research

05 Dec 2025, 15:06 UTC · 47w ago

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Verdict

Headline takes no side. We score INGN +0.60 across six claims — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · INGN

+0.60strongly bullish

−1 bearish0bullish +1

More positive than 71% of ticker scores this week

Actual

Scored by the NIS engine · methodology.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

earnings growth▲200%
healthcare
INGN
competition
forex risk
medical devices
portable oxygen
value investing

Top 1 mover · tap to explore

Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Create my briefing

What the story claims

6 claims · scored −1 bearish … +1 bullish

What matters in this story

1
Inogen projects 37.8% earnings growth for 2026 and anticipates continued business improvements going forward.
So whatA projected 37.8% earnings growth for a small-cap stock signals a potentially significant fundamental inflection point that would re-rate the stock if confirmed.
+0.70
More positive than 98% of claims this week
2
Inogen's P/S ratio stands at 0.5 compared to the industry average of 3.8, indicating a highly attractive valuation.
+0.60

Continue reading

5 related stories

Next reads from the same story arc

MarketBeat
1h ago
Adaptive Biotechnologies Q3 Earnings Call Highlights
- healthcare
Read

Read original · https://www.zacks.com/stock/news/2800164/here-s-why-you-should-add-inogen-stock-to-your-portfolio-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2800164

More positive than 92% of claims this week

3

Inogen's shares have lost 23.8% year-to-date, significantly underperforming both its industry (up 4.2%) and the S&P 500 (up 18.9%).

-0.50

More negative than 91% of claims this week

4

Inogen sold approximately 143,100 oxygen systems in the nine months ended Sept. 30, 2025, up 20.2% year over year.

+0.50

More positive than 84% of claims this week

5
Stiff competition and forex volatility remain major downside risks for Inogen.
So whatThese operational and macro headwinds introduce earnings uncertainty and could constrain margin expansion, weighing on investor confidence.
-0.40
More negative than 86% of claims this week
6
The global portable oxygen concentrator (POC) market is anticipated to grow from $1.58 billion in 2022 to $3.03 billion by 2030 at a CAGR of 8.5%.
+0.30
More positive than 60% of claims this week

Unlock 2 more claims

Which stocks this story touches

How each ticker is affected

INGN+0.60
More positive than 71% of ticker scores this week
The company is described as well-poised for growth with high prospects in the POC space and an attractive valuation, despite some headwinds from competition and forex.

Read next

AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results

Benzinga · 15h ago

healthcare
medical devices

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$INGN#competition#earnings_growth#forex_risk#healthcare

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

Zacks Investment Research

1h ago

Envista (NVST) Reports Q3 Earnings: What Key Metrics Have to Say

healthcare

Read

Zacks Investment Research

2h ago

Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates

healthcare

Zacks Investment Research

2h ago

Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates

healthcare

Seeking Alpha

3h ago

Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript

healthcare

=

Actual · 230 sessions

+3.3%

Price agrees with the score

$7.22 vs $6.99 close before publication (Dec 4) · not market-adjusted